Truist Securities Rates Janux Therapeutics (JANX) buy

Truist Securities raised its rating on Janux Therapeutics to Buy with a $26 price target, a 74.03% upside from the current price.

By EarningsIQ Research Desk · Published Jun 25, 2026, 11:01 AM EDT · Updated Jun 29, 2026, 12:02 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Truist Securities rated Janux Therapeutics, Inc. ($JANX) "buy" with a $26 price target on June 25, 2026.

Since the rating, $JANX is up 6.6% after 1 week, up 6.8% after 1 month and up 13.2% to date (from the $14.58 close on Jun 25, 2026).

JANX Janux Therapeutics, Inc.

$16.51 +20.95% year to date

Daily close · Oct 16, 2026

Key Points

Truist Securities upgraded Janux Therapeutics to a Buy rating with a $26 price target on June 25, 2026.
Truist Securities's $26 price target implies 74.03% upside from Janux Therapeutics, Inc.'s ($JANX) current $14.94 share price.
Janux Therapeutics' shares traded around $14.64 on Thursday, with a market cap of approximately $874.5 million.
Recent insider buying included multiple purchases on June 11, 2026, while analysts maintain mixed views on the stock.

Get $JANX trade alerts by text

We text you when insiders, Congress or big funds trade $JANX. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Janux Therapeutics, Inc. alert may contain errors. Disclosures

Truist Securities has upgraded its rating on Janux Therapeutics, Inc. (NasdaqGM: JANX) to Buy, setting a price target of $26. This upgrade was announced on June 25, 2026, by analyst Supawat Thongthip, marking a positive outlook for the biotechnology company.

Analyst rating track record

Truist Securities vs. the S&P 500

YTD return -3.46% hypothetical

All-time return +0.16% S&P 500 +24.84%

vs. S&P 500 -24.68% behind the index

Hypothetical returns from Truist Securities's disclosed trades, not real profit or advice. How we model this.

Other Institutional Activity in Janux Therapeutics

RA Capital Management, L.P. held steady with 11,189,693 shares worth about $155.5 million. BlackRock, Inc. increased its stake by 1,353,033 shares, bringing its total to 5,433,233 shares valued at approximately $75.5 million, a 33.2% rise. Meanwhile, Janus Henderson Group PLC reduced its holdings by 1,154,044 shares, leaving it with 4,196,409 shares worth about $58.3 million, a 21.6% decrease. Prosight Management, LP expanded its position by 1,157,477 shares to 3,550,000 shares, valued at about $49.3 million, a 48.4% increase. FMR LLC cut its stake by 976,660 shares, ending with 2,535,724 shares valued at $35.2 million, a 27.8% decrease.

Janux Therapeutics, Inc. Stock Down 9.9%

Shares of Janux Therapeutics traded near $14.64 on Thursday. The company has a market cap of approximately $874.5 million. Although it isn't profitable, its forward P/E ratio is -5.17, and it has a beta of 2.52, indicating higher volatility. The stock's 52-week range is between $12.12 and $35.34, with a 50-day moving average of $14.41 and a 200-day moving average of $18.05.

12-month forecast

$JANX price target

Janux Therapeutics, Inc. daily closes and this analyst's $26 target. Not advice.

Recent Earnings

For its most recent quarter, Janux Therapeutics reported revenue of $13.73 million. However, the company is not yet profitable, with a negative return on equity of -11.7%. The next earnings release is expected on August 6, 2026.

Insider Buying and Selling at Janux Therapeutics, Inc.

On June 11, 2026, several insiders, including Winston Kung, Ronald Barrett, and Natasha Hernday, purchased shares. Each insider acquired 5,500 shares, while RA Capital Management and Vickie Capps bought 15,500 shares each.

Analysts Set New Price Targets

On June 25, 2026, Truist Securities assumed coverage with a Buy rating and a $26 price target. Piper Sandler and Wedbush both maintained Buy ratings on May 8, 2026, with targets of $26 and $36, respectively. Guggenheim also maintained a Buy rating with a $58 target. In contrast, Barclays downgraded the stock to Sell with a $14 target on April 20, 2026.

About Janux Therapeutics

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in San Diego, California. It focuses on developing innovative immunotherapies using its proprietary TRACTr, TRACIr, and ARM platforms. The company targets various cancers, with clinical candidates like JANX007 and JANX008 in Phase 1 trials. Led by CEO Dr. David Alan Campbell, the company engages in strategic collaborations with major pharmaceutical companies like Merck and Bristol Myers Squibb.

Bottom Line

Truist Securities' upgrade to a Buy rating suggests confidence in Janux Therapeutics' potential, especially given its innovative cancer therapies. While the stock's past performance has been volatile, ongoing insider buying and strategic partnerships might attract investor interest. As always, it's important to remember that analyst ratings are based on past data and may not reflect future performance.